Literature DB >> 27771711

Clinical Therapeutic Effects of Aspirin in Combination with Fufang Danshen Diwan, a Traditional Chinese Medicine Formula, on Coronary Heart Disease: A Systematic Review and Meta-Analysis.

Jianchun Huang1, Xiaojun Tang, Fangxing Ye, Junhui He, Xiaolong Kong.   

Abstract

BACKGROUND/AIMS: Coronary heart disease is characterized by vascular stenosis or occlusion resulting in myocardial ischemia, hypoxia and necrosis. In China, the combination of aspirin and Fufang Danshen Diwan (FDD), a traditional Chinese medicine formula, has been suggested in the treatment of coronary heart disease. There have been several studies comparing the effectiveness of aspirin alone and in combination with FDD to treat coronary artery disease; however, it remains unclear whether combined aspirin therapy is superior. This study was thus designed to clarify this issue through a systematic review and meta-analysis.
METHODS: Databases including PubMed, EMBASE, China National Knowledge Infrastructure (CNKI) database, Wanfang Data and VIP Information were searched. Papers were reviewed systematically by two researchers and analyzed using Cochrane software Revman 5.1.
RESULTS: Fourteen randomized controlled trials enrolling 1367 subjects were included. Meta-analyses revealed that aspirin in combination with FDD was significantly more effective at alleviating angina pectoris and improving electrocardiogram (ECG) results relative to aspirin therapy alone, reflected by the summary effects for the clinical markedly effective (OR = 2.45; 95% CI 1.95-3.08) and the total effective (OR = 3.92; 95% CI 2.87-5.36) rates. In addition, combined aspirin and FDD was significantly more efficacious than aspirin monotherapy at improving blood lipid levels, as indicated by the following outcomes: 1) reduction of TC level (SMD -1.12; 95% CI -1.49 to -0.76); 2) reduction of TG level (SMD -0.94; 95% CI -1.15 to -0.74); 3) reduction of LDL level (SMD -0.68; 95% CI -0.88 to -0.48); and 4) improvement of HDL level (SMD 0.52; 95% CI 0.04 to 0.99 ). No serious adverse events were reported in any of the included trials.
CONCLUSION: The present meta-analysis demonstrated that aspirin in combination with FDD was more effective than aspirin alone for treating coronary heart disease. More full-scale randomized clinical trials with reliable designs are recommended to further evaluate the clinical benefits and long-term effectiveness of FDD for the treatment of coronary heart disease.
© 2016 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27771711     DOI: 10.1159/000447892

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  13 in total

1.  Cluster analysis for syndromes of real-world coronary heart disease with angina pectoris.

Authors:  Yufeng Zhao; Xueyun Yu; Xinyu Cao; Lin Luo; Liyun He; Shusong Mao; Li Ma; Peijing Rong; Yuxue Zhao; Guozheng Li; Baoyan Liu
Journal:  Front Med       Date:  2017-12-05       Impact factor: 4.592

2.  A Systematic Review and Meta-Analysis of Phytoestrogen Protects Against Myocardial Ischemia/Reperfusion Injury: Pre-Clinical Evidence From Small Animal Studies.

Authors:  Yumeng Wang; Xintian Shou; Zongjing Fan; Jie Cui; Donghua Xue; Yang Wu
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

3.  Lentinan combined with cisplatin for the treatment of non-small cell lung cancer.

Authors:  Chenchen Zhao; Haifeng Yan; Wentai Pang; Tong Wu; Xianbin Kong; Xiaojiang Li; Honggen Liu; Linlin Zhao; Feng Liang; Yingjie Jia
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

4.  Effectiveness and safety of modified 'Huoxue Shugan' formulas on coronary heart disease combined with depression: protocol for a systematic review.

Authors:  Mingtai Chen; Ling Men; Lijun Ou; Tao Li; Meihuan Li; Xiaoling Zhong; Jian Zhang; Zhong Zhang
Journal:  BMJ Open       Date:  2018-11-03       Impact factor: 2.692

5.  Clinical study of chlamydia pneumoniae infection in patients with coronary heart disease.

Authors:  Lei Xue; Yan-Hong Liang; Yuan-Yuan Gao; Xiao-Juan Wang
Journal:  BMC Cardiovasc Disord       Date:  2019-05-14       Impact factor: 2.298

6.  AFC1 Compound Attenuated MI/R-Induced Ventricular Remodeling via Inhibiting PDGFR and STAT Pathway.

Authors:  Jie Liu; Xiaohui Zhou; Qingshu Meng; Kevin W Huang; Jing Liu; Jinjun Tie; Rulin Zhuang; Guohan Chen; Yuhui Zhang; Lu Wei; Li Huang; Chun Guang Li; Binghui Wang; Huimin Fan; Zhongmin Liu
Journal:  Front Pharmacol       Date:  2019-10-15       Impact factor: 5.810

7.  Exploring the mechanism of Shengmai Yin for coronary heart disease based on systematic pharmacology and chemoinformatics.

Authors:  Yan Jiang; Qi He; Tianqing Zhang; Wang Xiang; Zhiyong Long; Shiwei Wu
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

8.  Mining of candidate genes involved in the biosynthesis of dextrorotatory borneol in Cinnamomum burmannii by transcriptomic analysis on three chemotypes.

Authors:  Zerui Yang; Wenli An; Shanshan Liu; Yuying Huang; Chunzhu Xie; Song Huang; Xiasheng Zheng
Journal:  PeerJ       Date:  2020-06-10       Impact factor: 2.984

9.  A systematic review of the effectiveness and safety of Chinese herbal medicine formula Gualou Xiebai Banxia (GLXBBX) decoction for the treatment of stable angina pectoris.

Authors:  Mingtai Chen; Ling Men; Haibin Wu; Guofu Zhong; Lijun Ou; Tao Li; Yingyi Guo; Haidan Lin; Jian Zhang; Dongcai Wang; Zhong Zhang
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

10.  Effectiveness and safety of Chinese herbal medicine formula Gualou Xiebai Banxia (GLXBBX) decoction for the treatment of stable angina pectoris: Protocol for a systematic review.

Authors:  Mingtai Chen; Meihuan Li; Lijun Ou; Rongren Kuang; Yingnan Chen; Tao Li; Ling Men; Jian Zhang; Zhong Zhang
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.